Description
AOD-9604 Peptide for sale
AOD‑9604 Peptide Research Overview
AOD 9604 is a modified fragment of human growth hormone (hGH) that has been studied primarily for its lipolytic (fat‑reducing) properties and regenerative potential. Below is a summary of key findings from animal experiments, human trials and laboratory research. Please note: all information is for educational purposes only—AOD 9604 is a research compound and is not approved for human use.
AOD 9604 for sale – Lipolytic Activity in Obesity Models
- Obese Zucker rat study: Daily oral dosing of AOD 9604 (500 µg/kg) for 19 days reduced body‑weight gain by more than 50 % compared with untreated controls (approximately 16 g vs. 36 g). Adipose tissue from treated animals showed higher lipolytic activity, and the peptide did not impair insulin sensitivity【PubMed: 11146367】【PubMed: 11713213】.
- Together, these animal data indicate that AOD 9604 may promote fat breakdown and limit weight gain through enhanced energy expenditure and fat oxidation.
AOD 9604 peptides for sale Human Clinical Evidence
- Phase II trial (12 weeks): In a double‑blind, placebo‑controlled study, obese adults received AOD 9604 (0–30 mg/day) for 12 weeks. Participants taking 1 mg/day lost about 2.6 kg, while those on placebo lost 0.8 kg. Weight loss was not dose‑dependent, and a later 24‑week trial failed to show significant benefit【PubMed: 20445536】.
- Safety: Clinical studies report that AOD 9604 does not alter IGF‑1 levels, does not disrupt carbohydrate metabolism, does not provoke an immune response, and shows a safety profile comparable to placebo【PubMed: Safety study】.
AOD-9604 for sale – Tissue Regeneration and In‑Vitro Studies
- Rabbit osteoarthritis model: New Zealand white rabbits with collagenase‑induced knee osteoarthritis were given weekly intra‑articular injections of saline, hyaluronic acid (HA), AOD 9604 or AOD 9604 + HA. Animals receiving AOD 9604 + HA showed the lowest cartilage‑degeneration scores and the shortest lameness period. AOD 9604 alone also outperformed saline and HA alone【PubMed: 26275694】.
- Cell culture findings: Patent‑related data indicate that AOD 9604 (10 µg/mL) increased proteoglycan and collagen production in bovine chondrocytes and accelerated differentiation of C2C12 myoblasts, suggesting a possible role in cartilage repair and muscle development.
Cancer‑Related Research
- Nanoparticle co‑delivery study: A 2022 investigation used chitosan nanoparticles to co‑deliver doxorubicin and AOD 9604 to MCF‑7 breast cancer cells. Dual‑loaded nanoparticles exhibited greater anti‑proliferative activity than doxorubicin‑only nanoparticles. The authors concluded that AOD 9604 may enhance drug accumulation in tumors and reduce off‑target toxicity【PubMed: 9249349】.
Conclusion and Research‑Only Notice
Early animal and in‑vitro studies suggest that AOD 9604 can stimulate lipolysis, reduce weight gain, and aid cartilage repair without the metabolic side effects associated with full‑length hGH. Human trials show modest weight loss and a favorable safety profile, but long‑term efficacy remains unproven. In vitro work hints at regenerative and anticancer applications. However, AOD 9604 remains an investigational compound—rigorous clinical studies are required to determine its therapeutic potential. All products containing AOD 9604 are strictly intended for laboratory research and are not designed for human consumption.
PLEASE NOTE THAT ALL PRODUCTS FEATURED HERE ARE INTENDED EXCLUSIVELY FOR RESEARCH AND DEVELOPMENT PURPOSES. THEY ARE NOT DESIGNED FOR ANY FORM OF HUMAN CONSUMPTION. THESE PRODUCTS HAVE NOT UNDERGONE EVALUATION BY THE U.S. FOOD AND DRUG ADMINISTRATION.
